NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,490.54% | 889.83% | 32.73% | -83.76% | -85.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,490.54% | 889.83% | 32.73% | -83.76% | -85.41% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,490.54% | 889.83% | 32.73% | -83.76% | -85.41% |
| SG&A Expenses | 99.40% | 101.71% | 67.12% | 79.27% | 103.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.95% | 3.08% | 24.11% | 17.33% | 54.53% |
| Operating Income | 15.36% | 49.55% | -23.76% | -39.22% | -81.97% |
| Income Before Tax | -86.34% | 64.68% | -1.87% | -123.16% | -30.03% |
| Income Tax Expenses | -100.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.23% | 64.68% | -1.87% | -123.16% | -30.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.23% | 64.68% | -1.87% | -123.16% | -30.10% |
| EBIT | 15.36% | 49.55% | -23.76% | -39.22% | -81.97% |
| EBITDA | 15.44% | 49.59% | -23.75% | -39.21% | -81.94% |
| EPS Basic | -54.47% | 69.26% | 11.72% | -312.07% | 97.36% |
| Normalized Basic EPS | -32.81% | 72.18% | -11.21% | -282.73% | 97.15% |
| EPS Diluted | -54.47% | 69.26% | 11.72% | -312.07% | 97.36% |
| Normalized Diluted EPS | -32.81% | 72.18% | -11.21% | -282.73% | 97.15% |
| Average Basic Shares Outstanding | 20.56% | 14.90% | 15.41% | 116.62% | 4,826.12% |
| Average Diluted Shares Outstanding | 20.56% | 14.90% | 15.41% | 116.62% | 4,826.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |